Cognito Therapeutics, Inc.

📍 Cambridge, United States🗓 Founded 2016👥 58 employees💰 Last funded Jun 2022
Medical Equipment Manufacturing🌐 cognitotx.com
Website LinkedIn
Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.
4
Total investors
1
Early stage
1
Mid stage
2
Late stage
2016
Founded

Investors

4 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
4
Investor activity2016–2022 · investors recorded per year
201612020120222
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Cognito Therapeutics, Inc.?
Cognito Therapeutics, Inc. has 4 investors on record on gritt.io, including 1 early-stage backers, 1 mid-stage and 2 late-stage investors.
When did Cognito Therapeutics, Inc. last raise funding?
The most recent investment in Cognito Therapeutics, Inc. recorded on gritt.io was in June 2022.
When was Cognito Therapeutics, Inc. founded?
Cognito Therapeutics, Inc. was founded in 2016.
What industry is Cognito Therapeutics, Inc. in?
Cognito Therapeutics, Inc. operates in Medical Equipment Manufacturing. Find similar Medical Equipment Manufacturing investors on gritt.io.
Where is Cognito Therapeutics, Inc. based?
Cognito Therapeutics, Inc. is headquartered in Cambridge, United States.